Direct oral anticoagulants (DOACs) have been a breakthrough therapy for adults with nonvalvular atrial fibrillation and venous thromboembolic disease, disease states for which these drugs have been approved by the US Food and Drug Administration. However, these therapies are not a panacea. Most notably, warfarin remains the standard of care for those with mechanical valves. The Randomised, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients After Heart Valve Replacement (RE-ALIGN) trial, a phase 2 study of dabigatran vs warfarin, was stopped early because of excess thromboembolic and bleeding events in those receiving dabigatran compared with those receiving warfarin.1
Navar AM, Mehran R. High Rates of Off-label Prescribing and the Urgent Need for a Randomized Clinical Trial. JAMA Cardiol. 2020;5(6):692–693. doi:10.1001/jamacardio.2020.0612
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: